Related Experiment Video
Updated: Jun 15, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored
James Matcham1, Steven Julious, Stephen Pyke
1Amgen Ltd., Global Biostatistics and Epidemiology, Cambridge, UK. jamesm@amgen.com
Abstract:
In this paper we set out what we consider to be a set of best practices for statisticians in the reporting of pharmaceutical industry-sponsored clinical trials. We make eight recommendations covering: author responsibilities and recognition; publication timing; conflicts of interest; freedom to act; full author access to data; trial registration and independent review. These recommendations are made in the context of the prominent role played by statisticians in the design, conduct, analysis and reporting of pharmaceutical sponsored trials and the perception of the reporting of these trials in the wider community.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Statistical Software for Data Analysis and Clinical Trials
